Hmong
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Khoom Categories
Cov khoom tshwj xeeb
Lenopril ntsiav tshuaj txhawb kev tswj ntshav siab thiab mob plawv

Lenopril ntsiav tshuaj txhawb kev tswj ntshav siab thiab mob plawv
Telmisartan Zoo dua antihypertensive Tiv thaiv lub raum

Telmisartan Zoo dua antihypertensive Tiv thaiv lub raum
Flumazenil A Selective GABAA Receptor Antagonist thiab nws cov kev siv kho mob

Flumazenil A Selective GABAA Receptor Antagonist thiab nws cov kev siv kho mob
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers

Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers
Tirzepatide Dual GLP-1 thiab GIP Receptor Agonist rau Kev Tswj Qhov hnyav thiab Glycemic Control

Tirzepatide Dual GLP-1 thiab GIP Receptor Agonist rau Kev Tswj Qhov hnyav thiab Glycemic Control
Cisapride Gastric Stimulant rau Indigestion thiab Digestive Disorders

Cisapride Gastric Stimulant rau Indigestion thiab Digestive Disorders
YK-11 Muaj peev xwm SARM rau Lub Tsev Muscle, Lub Zog Tau Txais, thiab Myostatin Inhibition

YK-11 Muaj peev xwm SARM rau Lub Tsev Muscle, Lub Zog Tau Txais, thiab Myostatin Inhibition
Ostarine (MK-2866) Ntau yam SARM rau Cov leeg nqaij loj hlob, rog poob, thiab lub cev rov ua haujlwm

Ostarine (MK-2866) Ntau yam SARM rau Cov leeg nqaij loj hlob, rog poob, thiab lub cev rov ua haujlwm
MK-677 Unique Compound rau cov leeg loj hlob, kev ua siab ntev, thiab rov qab los

MK-677 Unique Compound rau cov leeg loj hlob, kev ua siab ntev, thiab rov qab los
0102 ib0304 ib05
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers
Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers

Dabrafenib Lub Hom Phiaj Kev Kho Mob rau BRAF-Mutated Cancers

Peference Nqe: USD 50-60 / kg

  • Khoom npe Dabrafenib
  • CAS Nr. 1195765-45-7
  • MF C23H20F3N5O2S2
  • MW 519.561 ib
  • EINECS 1592732-453-0
  • Qhov ntom 1.443 ib
  • Boiling point 653.726 ° C ntawm 760 mmHg
Tiv tauj peb
cov khoom paub meej

Cov lus piav qhia ntxaws

Dabrafenib yog ib qho bioavailable inhibitor ntawm B-raf (BRAF) protein thiab yog siv los ua tshuaj tiv thaiv kab mob cancer. Nws xaiv hom mob qog noj ntshav cuam tshuam nrog kev hloov pauv ntawm BRAF noob. Kab lus no tshawb txog cov txheej txheem ntawm kev nqis tes ua, kev tshuaj ntsuam xyuas, thiab kev siv dabrafenib hauv kev kho mob qog noj ntshav.

I. Nkag siab Dabrafenib:
A. Inhibitor ntawm B-raf (BRAF) protein
B. Mechanism ntawm kev txiav txim: thaiv qhov txawv txav ntawm cov protein qhia thiab tswj kev loj hlob ntawm tes

17159473034104h 3

II. Clinical Indications:

A. Monotherapy:

Unreectable los yog metastatic melanoma nrog BRAF V600E kev hloov

B. Combination therapy nrog trametinib:

BRAF V600E-zoo unresectable los yog metastatic melanoma

Metastatic non-me me mob ntsws cancer

Metastatic anaplastic thyroid cancer

Unreectable los yog metastatic khoom hlav


III. Mechanism ntawm Action:

A. Kev xaiv khi thiab inhibition ntawm B-raf

B. Inhibition ntawm qog cell proliferation nrog mutated BRAF noob


IV. Kev kho mob ntawm Thyroid Cancer:

A. Qee hom mob qog noj ntshav uas tau kis mus rau cov ntaub so ntswg nyob ze lossis lwm qhov hauv lub cev

B. Kev kho mob yav dhau los


V. Kinase Inhibitor Chav Kawm:

A. Dabrafenib ua ib tug tswv cuab ntawm kinase inhibitors

B. Tiv thaiv kev ua haujlwm tsis zoo ntawm cov protein kom tiv thaiv kab mob qog noj ntshav


Dabrafenib yog ib hom kev kho mob uas siv rau hauv kev kho mob BRAF-mutated cancers. Raws li ib qho inhibitor ntawm B-raf (BRAF) protein, nws xaiv lub hom phiaj qog hlwb uas muaj cov noob BRAF hloov pauv, inhibiting lawv cov kev loj hlob. Dabrafenib yog qhia rau unreectable los yog metastatic melanoma, non-small cell ntsws cancer, anaplastic thyroid cancer, thiab unreectable los yog metastatic khoom qog. Kev sib xyaw ua ke nrog trametinib txuas ntxiv nthuav dav nws cov ntawv thov. Los ntawm kev nkag siab txog cov kev hloov pauv caj ces hauv cov qog nqaij hlav cancer, cov kev kho mob xws li dabrafenib ua lub luag haujlwm tseem ceeb hauv kev txhim kho cov txiaj ntsig kev kho mob thiab inhibiting kev sib kis ntawm cov qog nqaij hlav cancer.

Specification

1715947563669 qd1